{"paper_id":"afa234a7-affe-486a-99b3-f0b2718e626c","body_text":"Correlation of Serum CA-125 and CA-19-9 Levels with the Severity of Endometriosis: A Cross-Sectional Study\nDOI:\nhttps://doi.org/10.70818/pjaog.v05i01.0190Keywords:\nEndometriosis, CA-125, CA-19-9, Biomarker, Disease Severity, R-AFS StagingAbstract\nBackground: Endometriosis is a chronic, estrogen-dependent gynecological disorder characterized by the presence of endometrial-like tissue outside the uterine cavity. Diagnosis relies on invasive laparoscopy, and noninvasive biomarkers such as CA-125 and CA-19-9 have been investigated to reflect disease severity. Objective: To evaluate the relationship between serum CA-125 and CA-19-9 levels and the severity of endometriosis, assessing their potential role as noninvasive biomarkers. Materials and Methods: This cross-sectional comparative study was conducted at the Department of Obstetrics and Gynaecology, Bangladesh Medical University, Dhaka, from January 2013 to August 2014. Seventy women undergoing laparoscopy or laparotomy for suspected pelvic or ovarian endometriosis were included. Serum CA-125 and CA-19-9 were measured preoperatively using the IMMULITE 2000 immunoassay. Endometriosis was staged intraoperatively according to the Revised American Fertility Society (R-AFS) classification. Statistical analysis included mean ± SD calculation, one-way ANOVA, and Spearman’s rank correlation. Results: Among 70 patients, Stage I, II, III, and IV endometriosis were observed in 10%, 20%, 24.3%, and 45.7%, respectively. Mean CA-125 levels increased significantly with disease severity (Stage I: 21.8 ± 15.1 U/mL; Stage IV: 117.0 ± 41.6 U/mL; p = 0.001). Similarly, mean CA-19-9 levels rose progressively (Stage I: 8.4 ± 5.2 U/mL; Stage IV: 38.8 ± 29.6 U/mL; p = 0.001). Spearman’s correlation showed a strong positive association between CA-19-9 and disease stage (ρ = 0.674, p < 0.001) and a moderate correlation for CA-125 (ρ = 0.547, p < 0.001). Conclusion: Serum CA-125 and CA-19-9 levels correlate positively with endometriosis severity. Although neither marker is specific enough for standalone diagnosis, their combined measurement may assist in reflecting disease burden and guiding clinical assessment alongside laparoscopic evaluation.\nReferences\n1. Mcleod BS, Retzloff MG. Epidemiology of endometriosis: an assessment of risk factors. Clin Obstet Gynecol. 2010;53(2):389-96.\n2. Koninckx PR, Ussia A, Alsuwaidi S, Amro B, Keckstein J, Adamyan L, Donnez J, Martin MC, Wattiez A. Reconsidering evidence-based management of endometriosis. Facts, Views & Vision in Obgyn. 2022 Sep 30;14(3):225.\n3. Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, Tatebe K, Veneris JL. Current recommendations and recent progress in endometrial cancer. CA: a cancer journal for clinicians. 2019 Jul;69(4):258-79.\n4. Liu E, Nisenblat V, Farquhar C, Fraser I, Bossuyt PM, Johnson N, Hull ML. Urinary biomarkers for the non-invasive diagnosis of endometriosis. Cochrane Database Syst Rev. 2015;12:CD012019.\n5. Aziz S, Amir SS, Ihsanullah HS, Khan UA, Shams S. Is serum human epididymis protein HE4 more specific than cancer antigen-125 in patients with benign gynecological diseases? Pak J Med Health Sci. 2023;17(3):214.\n6. Monowara Begum, Tripty Rani Das, Sadia Jabeen Khan, Suriya Khanom, Nasrin Akter, Mahmud-Un-Nabi. Correlation of CA 125 and CA 19-9 Levels with the Severity of Endometriosis in a Tertiary Care Hospital. East Afr Scholars J Med Sci. 2024;7(12):525-30.\n7. Feduniw S, Pruc M, Ciebiera M, Safiejko K, Bizon M, Szarpak L. Current evidence on CA-125 levels in differentiation between endometriomas and endometriosis-associated ovarian cancer: a systematic review and meta-analysis. J Endometr Pelvic Pain Disord. 2024;16(3-4):154-9.\n8. Rokhgireh S, Mehdizadeh Kashi A, Chaichian S, Delbandi AA, Allahqoli L, Ahmadi-Pishkuhi M, Khodaverdi S, Alkatout I. The diagnostic accuracy of combined enolase/Cr, CA125, and CA19‐9 in the detection of endometriosis. BioMed Research International. 2020;2020(1):5208279.\n9. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. Ca Cancer J Clin. 2021 May;71(3):209-49.\n10. Taniguchi F, Harada T, Kobayashi H, Hayashi K, Momoeda M, Terakawa N. Clinical characteristics of patients in Japan with ovarian cancer presumably arising from ovarian endometrioma. Gynecologic and obstetric investigation. 2014 Feb 5;77(2):104-10.\n11. Kadan Y, Fiascone S, McCourt C, Raker C, Granai CO, Steinhoff M, Moore RG. Predictive factors for the presence of malignant transformation of pelvic endometriosis. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2015 Feb 1;185:23-7.\n12. Gentry-Maharaj A, Burnell M, Dilley J, Ryan A, Karpinskyj C, Gunu R, Mallett S, Deeks J, Campbell S, Jacobs I, Sundar S. Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses. American journal of obstetrics and gynecology. 2020 Jan 1;222(1):56-e1.\n13. Harada T, Kubota T, Aso T. Usefulness of CA19-9 versus CA125 for the diagnosis of endometriosis. Fertil Steril. 2002;78(4):733-739.\n14. Shen A, Xu S, Ma Y, Guo H, Li C, Yang C, Zou S. Diagnostic value of serum CA125, CA19-9 and CA15-3 in endometriosis: a meta-analysis. J Int Med Res. 2015;43(5):599-609.\n15. Amaral VF, Ferriani RA, Sá MFS, Nogueira AA, Silva JCR, Silva ACJDSR, Moura MDD. Positive correlation between serum and peritoneal fluid CA-125 levels in women with pelvic endometriosis. Sao Paulo Med J. 2006;124:223–227.\n16. Yang H, Chang R, Huang B. Serum markers in the evaluation of endometriosis: an analysis of CA 125 and CA 19-9. J Obstet Gynaecol Res. 2004;30(2):98–102.\n17. Pados G, Laskaridis K, Papadaki I. The diagnostic value of serum CA 125 and CA 19-9 in endometriosis. Eur J Obstet Gynecol Reprod Biol. 2016;204:123–128.\n18. Al-Tai AM, Shams T, Mansour MS. The role of CA 125 and CA 19-9 in the diagnosis and staging of endometriosis. J Obstet Gynaecol. 2014;34(1):25–30.\n19. Toki T, Kubota J, Lu X, Nakayama K. Immunohistochemical analysis of CA125, CA19–9, and Ki-67 in stage III or IV endometriosis: positive correlation between serum CA125 level and endometriotic epithelial cell proliferation. Acta Obstet Gynecol Scand. 2000;79(9):771–776.\n20. Xavier S, Voss J, Beck K. Correlation of CA 125 levels with the stage of endometriosis. J Reprod Med. 2005;50(4):271–276.\n21. Yu Z, Sun Y, Guo CS. Evaluating pretreatment serum CA-125 levels as prognostic biomarkers in endometrial cancer: a comprehensive meta-analysis. Front Oncol. 2024;14:1442814. doi:10.3389/fonc.2024.1442814.\nDownloads\nPublished\nIssue\nSection\nLicense\nCopyright (c) 2026 Runa Laila, Shabnam Banu, Shamima Yasmin, Kazi Sadeka Ruma, Mst Fazila Tunnesa, Khaleda Asma (Author)\nThis work is licensed under a Creative Commons Attribution 4.0 International License.","source_license":"CC0","license_restricted":false}